What Swiss does

Swiss Parenterals Limited is an Ahmedabad-based pharmaceutical contract development and manufacturing organization (CDMO) founded in 1986, specializing in generic and specialty sterile injectables alongside a broader portfolio spanning inhaled anesthetics, orals, ophthalmic/nasal, semi-solids, nutritional OTC, ayurvedic/cosmetics, and veterinary products. The company operates three cGMP-compliant manufacturing units in Ahmedabad equipped with dedicated HVAC/BMS/EMS systems, automated sterile and oral dosage lines, lyophilization, pre-filled syringe filling, and cephalosporin/betalactam/carbapenem dry powder injectable capabilities, supported by GLP-certified QC laboratories and ERP-driven batch release and ICH stability testing. Its product portfolio exceeds 250 SKUs across approximately 190 unique molecules with over 1,000 approved dossiers, and the company holds EU-GMP, PIC/s, ANVISA, TGA, and Cofepris certifications enabling exports to 80+ countries under both its own brand and partner labels.

Swiss generates revenue through three primary streams: (1) international distribution partnerships, supplying both own-brand and partner-labeled generic/specialty injectables to B2B distributors in 80+ countries with regulatory dossier support; (2) contract manufacturing services for medicinal products (Rx, OTC, and dietary supplements) under cGMP-compliant production with full analytical support; and (3) technology transfer and licensing services including analytical method transfer, AMV per ICH guidelines, and dossier creation/submission support. Pricing is not publicly disclosed; quotes are negotiated based on volume and specification. As of November 2025, Swiss became a wholly-owned subsidiary of Eris Lifesciences via a share-swap acquisition of the remaining 30% stake, with Naishadh Shah appointed Managing Director and FY27 identified as a significant year for the company's international expansion under Eris' strategic umbrella.

Name

Swiss

Legal name

Swiss Parenterals Limited

Website

https://swiss.in

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Swiss Parenterals is an Ahmedabad-based CDMO manufacturing generic and specialty sterile injectables, inhaled anesthetics, orals, ophthalmic, and nutritional products across three cGMP-certified units, exporting to 80+ countries for international distribution partners and as a wholly-owned Eris Lifesciences subsidiary since November 2025.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE), Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD)

Keywords

• Sterile injectables manufacturing
• Contract pharmaceutical manufacturing
• Generic pharmaceuticals export
• Inhaled anesthesia products
• Lyophilized injection production

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Exports: Swiss exports pharmaceutical products under its own brand name to over 80 countries globally, as well as products labeled in distribution partners' brands. Revenue is generated through direct B2B sales to international distribution partners with regulatory support provided across all activities.
2. Contract Manufacturing Services: The company offers customized contract manufacturing services with micro-control and monitoring and full analytical support at cGMP-compliant production plants. Services include manufacturing of medicinal products (Rx and OTC) and dietary supplements for third-party clients.
3. Technology Transfer and Licensing: Provides technology transfer services to distribution partners, including analytical method transfer, AMV in accordance with ICH guidelines, and comprehensive dossier creation and submission support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Swiss Parenterals is a contract development and pharmaceutical manufacturing company that produces sterile injectable dosage forms (lyophilized injections, pre-filled syringes, dry powder vials, liquid ampoules), inhaled anesthetics, oral solid dosages, ophthalmic and nasal products, semi-solids, and nutritional supplements. The company exports to 80+ countries under its own brand and partner brands, and provides contract manufacturing, technology transfer, analytical method transfer, dossier creation, and regulatory support to distribution partners and third-party clients.

Product overview

Swiss Parenterals is a third-generation family-owned Indian pharmaceutical company leveraging over 25 years of expertise in generic and specialty pharmaceuticals. The company operates as a manufacturer and exporter of sterile injectable products, offering a comprehensive portfolio across seven core product categories: Parenterals (injectable formulations including lyophilized injections, anaesthetics, and antibiotics), Inhaled Anesthesia (surgical anesthesia products), Ophthalmic and Nasal (eye drops, ear drops, and nasal sprays), Orals (tablets, capsules, and oral suspensions), Semi-Solids (topical creams, ointments, and gels), Nutritional/OTC (supplements and wellness products), and Ayurvedic/Cosmetics (traditional medicine and personal care). With over 1,000 approved dossiers and more than 190 unique molecules, Swiss exports to 80+ countries under its own brand name and partner brands. The company operates three manufacturing units in Ahmedabad, Gujarat, equipped with cGMP-compliant production facilities and serves international markets through regulatory approvals including EU-GMP, ANVISA, TGA, PIC/s, and Cofepris.

Differentiator

Problem solved

Functional benefit

Products and services

• Parenterals

Quantifiable outcome

• Products exported to 80+ countries globally
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian generic pharmaceutical company with a dedicated sterile injectables franchise and global commercial footprint; competes with Swiss in international tender and distribution channels but at significantly greater scale and brand recognition.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a broad sterile injectables and specialty portfolio (including inhalation anesthesia via Taro and other units), serving as a broader incumbent competitor across Swiss's product categories.
• Piramal Pharma Solutions: Global contract development and manufacturing organization with a strong sterile injectable and inhalation anesthesia franchise, competing with Swiss for partner-led contract manufacturing and technology transfer opportunities.
• Cadila Healthcare (Zydus): Indian pharmaceutical major with global sterile injectable manufacturing operations and an established international distribution presence that overlaps with Swiss's dossier-driven export business.

Direct peers

• Gland Pharma: Indian-headquartered sterile injectable manufacturer with global regulatory approvals and a B2B contract development and manufacturing model nearly identical to Swiss Parenterals, including lyophilized injectables, pre-filled syringes, and complex dosage forms sold through international distribution partners.
• Shilpa Medicare: Indian CDMO and specialty injectable producer with capabilities in lyophilized injectables, pre-filled syringes, and transdermal systems, targeting similarly regulated international markets through dossier and partner-led distribution.
• Aurobindo Pharma: Major Indian generic pharmaceutical manufacturer with a sizable sterile injectables franchise and a global export footprint spanning 150+ countries, overlapping directly with Swiss on lyophilized and liquid injectable generics.
• Bharat Serums and Vaccines: India-based specialty sterile injectable and biological products company focused on complex dosage forms (lyophilized, pre-filled syringes) for hospital and institutional channels — closely comparable to Swiss's higher-value injectable portfolio.

Emerging players

• Strides Pharma Science: Indian generic pharmaceutical company with regulated market focus and a portfolio of sterile injectables, oral solids, and soft gels, often partnering with international distributors in similar channels to Swiss.
• Alembic Pharmaceuticals: Indian generic manufacturer with growing injectable and international business, including US filings and sterile injectable capacity, comparable in scale and mid-tier positioning to Swiss.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiss